Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis
Veterinary Dermatology · 2025
DOI: 10.1111/vde.13319 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Veterinary Dermatology, 2025. Verfasst von Sophie Forster und 4 weiteren Autor:innen. Beteiligte Einrichtung: Elanco Animal Health Ltd, Hook, UK. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dog Diseases, Pruritus, Pyrimidines. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Janus kinase inhibitors (JAKi) have been shown to reduce pruritus and improve associated inflammatory skin lesions in canine atopic dermatitis (cAD).
Objective
To evaluate the efficacy and safety of ilunocitinib, in comparison to oclacitinib, for the control of cAD in a randomised, blinded trial. Animals Three‐hundred‐and‐thirty‐eight dogs with cAD. Materials and Methods Dogs were randomised to receive oclacitinib (0.4–0.6 mg/kg twice daily for 14 days; then once daily) or ilunocitinib (0.6–0.8 mg/kg once daily), for up to 112 days. Owners assessed pruritus using an enhanced Visual Analog Scale (PVAS). Investigators assessed skin lesions using the Canine Atopic Dermatitis Extent and Severity Index, 4th interaction (CADESI‐04).
Results
Reduction in pruritus and CADESI‐04 scores was similar for both treatment groups from Day (D)0–D14. PVAS scores increased between D14 and D28 for oclacitinib and decreased for ilunocitinib. On D28 to D112, mean PVAS and CADESI‐04 scores were significantly lower for ilunocitinib compared to oclacitinib ( p ≤ 0.003 and p ≤ 0.023, respectively). On D28 to D112, a greater number of ilunocitinib‐treated dogs achieved clinical remission of pruritus (i.e. PVAS score
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Elanco Animal Health Ltd, Hook, UK.
- Elanco Animal Health GmbH, Leverkusen, Germany.
- Elanco Animal Health, Greenfield, Indiana, USA.
Zitieren
APA
Forster, S., Boegel, A., Despa, S., Trout, C., & King, S. (2025). Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Veterinary Dermatology. https://doi.org/10.1111/vde.13319
Vancouver
Forster S, Boegel A, Despa S, Trout C, King S. Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Veterinary Dermatology. 2025. doi:10.1111/vde.13319
BibTeX
@article{Forster2025,
author = {Forster, Sophie and Boegel, Annette and Despa, Simona and Trout, Candace and King, Stephen},
title = {Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis},
journal = {Veterinary Dermatology},
year = {2025},
doi = {10.1111/vde.13319}
}
EUVIMED